Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: March 31, 2025 (Earliest event reported)
Sign-off Date: April 17, 2025
Context: The Company, incorporated in Delaware with principal offices in Australia, reported the entry into three material definitive agreements to secure financing for general working capital purposes.
Key Financial Metrics and Obligations
The filing details three distinct financing instruments entered into between March 31, 2025, and April 15, 2025. The filing does not provide consolidated revenue, profit, or cash flow statements.
| Instrument | Counterparty | Principal Amount | Purchase Price / Proceeds | Interest Rate / Cost | Maturity Date |
|---|---|---|---|---|---|
| Note 1 (Convertible) | Investor 1 | $55,000 | $50,000 | 8% p.a. (24% on default) | Dec 15, 2025 |
| Loan | Board Member | $63,188 AUD | $63,188 AUD | 12% p.a. (18% on default) | June 30, 2025 |
| Note 2 (Convertible) | Investor 2 | $79,200 | $67,000 | 15% one-time charge | Jan 30, 2026 |
Material Changes and Terms
- Note 1 (Investor 1): Issued at a discount ($50k for $55k principal). Conversion price is fixed at $5.00/share, dropping to $2.50/share if the stock trades below $4.00 for 5+ days. In default, conversion price resets to the lowest trading price of the prior 10 days. Prepayment is restricted after 180 days and carries significant premiums (110% to 125%) if exercised early.
- Loan (Board Member): Short-term bridge loan in AUD with monthly interest payments. Matures in June 2025.
- Note 2 (Investor 2): Issued at a discount ($67k for $79.2k principal). Includes a 15% upfront interest charge ($11,880). Repayment is structured in five installments starting September 30, 2025. Conversion is permitted only upon an Event of Default at a 35% discount to the lowest trading price of the prior 10 days. No prepayment penalty applies.
Management Commentary and Risks
- Use of Proceeds: All funds are designated for general working capital.
- Default Triggers: All instruments share common events of default, including failure to pay, failure to issue shares, failure to maintain OTC listing, failure to comply with SEC reporting, insolvency, or bankruptcy. Default accelerates repayment and, for Note 1, increases interest to 24%.
- Regulatory Status: Securities were issued under private placement exemptions (Section 4(a)(2) and Rule 506 of Regulation D).
Investor Verification Checklist
- Verify the current trading price of Propanc Biopharma common stock to assess the likelihood of Note 1's conversion price adjustment (triggered if price < $4.00 for 5 days).
- Confirm the Company's ability to meet the first installment payment for Note 2 due September 30, 2025 ($45,540).
- Review the Company's SEC reporting compliance status to ensure no default is triggered by late filings.
- Check the Company's OTC listing status to ensure it remains quoted on an approved platform.
- Assess the dilution impact if Note 1 or Note 2 is converted, particularly under default scenarios where conversion prices are significantly discounted.